Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK
- 25 August 2009
- journal article
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 19 (4), 425-433
- https://doi.org/10.1111/j.1365-2354.2009.01114.x
Abstract
The aim was to describe the clinical sequelae of patients treated with capecitabine in terms of adverse events, treatment modifications and therapy cessation throughout the treatment trajectory. A total of 1232 toxicity assessments were undertaken on colorectal and breast cancer patients receiving palliative and adjuvant treatment prior to treatment and at days 7, 14 and 21 for six cycles of chemotherapy. Most common adverse events were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue and pain which were experienced by over 80% of subjects. Grades 2 and 3 adverse events were common (n= 916 and n= 113) but their development into grade 4 was uncommon (n= 2). There was a downward trend in the percentage incidence of toxicity; however, PPE increased. Almost 60% of subjects completed six cycles, or planned treatment. Some 40% of subjects commenced treatment on a dose reduction (<1250 mg/m(2)), and this increased to 70% at cycle 6. In total, 2.8-11.6% of subjects experienced toxicity-related treatment deferrals. While adverse events are common with capecitabine the lack of grade 4 adverse events support the efficacy of current clinical management strategies. The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high-grade adverse events.Keywords
This publication has 13 references indexed in Scilit:
- Palmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreEuropean Journal of Oncology Nursing, 2007
- A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiencesEuropean Journal of Oncology Nursing, 2007
- Implementation of capecitabine (Xeloda®) into a cancer centre: UK experienceEuropean Journal of Oncology Nursing, 2004
- Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®)European Journal of Oncology Nursing, 2004
- A Changing Paradigm for Cancer Treatment: The Advent of New Oral Chemotherapy AgentsClinical Journal of Oncology Nursing, 2003
- Treatment for Anthracycline-Pretreated Metastatic Breast CancerThe Oncologist, 2002
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals Of Oncology, 2002
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) SyndromeAmerican Journal of Clinical Dermatology, 2000
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997